2 completed, 2 unknown, 1 terminated, 1 withdrawn. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Unknown 2, Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow protein analysis: new trials by email Literature Review of protein analysis trials Research Report on protein analysis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma defined green tea catechin extract, gene expression analysis, protein analysis - Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition | Phase 2 | Terminated | Barbara Ann Karmanos Cancer Institute | 8 | 2009-11-01 | 2015-03-27 |
| Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer cyclosporine, mycophenolate mofetil, pentostatin - Chronic Myeloproliferative Disorders, Leukemia | Phase 1 / Phase 2 | Withdrawn | University of Nebraska | 2008-09-01 | 2023-08-14 | |
| Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy erlotinib hydrochloride, sorafenib tosylate, DNA analysis - Lung Cancer | Phase 2 | Unknown | Yonsei University | 47 | 2008-09-01 | 2009-08-25 |
| Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma bortezomib, dexamethasone, pegylated liposomal doxorubicin hydrochloride - Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Unknown | Oncotherapeutics | 35 | 2008-07-01 | 2013-12-18 |
| Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors capecitabine, cisplatin, streptozocin - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Cambridge University Hospitals NHS Foundation Trust | 84 | 2005-08-01 | 2013-08-07 |
| Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma everolimus, DNA analysis, protein analysis - Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Completed | Mayo Clinic | 35 | 2005-03-01 | 2011-05-16 |
Multiple Myeloma (3) · Neoplasms, Plasma Cell (3) · Adenoma, Islet Cell (1) · Anemia, Aplastic (1) · Blast Crisis (1) · Carcinoma, Islet Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Congenital Abnormalities (1) · Gastrinoma (1) · Glucagonoma (1) · Insulinoma (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Acute (1)
Barbara Ann Karmanos Cancer Institute (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Mayo Clinic (1) · Oncotherapeutics (1) · University of Nebraska (1) · Yonsei University (1)
United States (2) · South Korea (1) · United Kingdom (1)
James R. Berenson, MD (1) · Jeffrey A. Zonder, MD (1) · Joo-Hang Kim, MD (1) · Pippa Corrie, PhD, FRCP (1) · Rafael Fonseca, MD (1) · Robert Bociek, MD (1) · Roy Vivek, MD (1) · Thomas E. Witzig, MD (1) · Tim Meyer, MD, BSc, MRCP, PhD (1)
P30CA015083 (1), P30CA022453 (1), P30CA036727 (1)